Regulation of Cellular Processes By ZCCHC13 (G389874)

Target Name: ZCCHC13

NCBI ID: G389874

ZCCHC13

Regulation of Cellular Processes By ZCCHC13

ZCCHC13 (ZCH13_HUMAN), a protein that belongs to the Zinc Finger Chromatin-H3 (ZFCH) gene family, plays a crucial role in cellular processes such as DNA replication, repair, and gene expression. ZCCHC13 is a key regulator of the expression of gene promoters, and its localization to the nuclear matrix has been implicated in various biological processes, including cancer development and progression.

Recent studies have identified ZCCHC13 as a potential drug target in cancer therapy. The ZFCH gene family has been implicated in the development and progression of various types of cancer, including breast, ovarian, and prostate cancers. ZCCHC13 has been shown to be overexpressed or underrepresented in various types of cancer, which may contribute to its potential as a drug target.

ZCCHC13 has been shown to play a role in the regulation of cellular processes that are important for cancer development. For example, ZCCHC13 has been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development and progression of cancer. ZCCHC13 has also been shown to be involved in the regulation of apoptosis, which is a critical programmed cell death that occurs in cancer cells.

In addition to its role in cell cycle progression and apoptosis, ZCCHC13 has also been shown to play a role in the regulation of gene expression. ZCCHC13 has been shown to interact with various transcription factors, including DNA replication factors, to regulate the expression of gene promoters. This interaction between ZCCHC13 and transcription factors suggests that it may be a useful biomarker for the diagnosis and prognosis of cancer.

The potential utility of ZCCHC13 as a drug target is further supported by its expression in various types of cancer. For example, ZCCHC13 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancers. Overexpression of ZCCHC13 has been shown to contribute to the development and progression of these cancers, which may make it an attractive target for cancer therapy.

In addition to its potential as a drug target, ZCCHC13 has also been shown to be a useful biomarker for the diagnosis and prognosis of cancer. For example, ZCCHC13 has been shown to be downregulated in various types of cancer, which may indicate a potential therapeutic target. Additionally, ZCCHC13 has been shown to be overexpressed in various types of cancer, which may indicate an increased risk of disease progression and poor prognosis.

In conclusion, ZCCHC13 is a protein that has been shown to play a crucial role in various cellular processes that are important for cancer development and progression. Its localization to the nuclear matrix and its interaction with transcription factors suggest that it may be a useful biomarker for the diagnosis and prognosis of cancer. Furthermore, its overexpression in various types of cancer suggests that it may be a potential drug target for cancer therapy. Further research is needed to fully understand the role of ZCCHC13 in cancer biology and its potential as a drug target .

Protein Name: Zinc Finger CCHC-type Containing 13

The "ZCCHC13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZCCHC13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets